Dosimetric and preparation procedures for irradiating biological models with pulsed electron beam at ultra-high dose-rate.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2019
Historique:
received: 30 11 2018
revised: 30 04 2019
accepted: 03 05 2019
pubmed: 9 6 2019
medline: 6 5 2020
entrez: 9 6 2019
Statut: ppublish

Résumé

Preclinical studies using a new treatment modality called FLASH Radiotherapy (FLASH-RT) need a two-phase procedure to ensure minimal uncertainties in the delivered dose. The first phase requires a new investigation of the reference dosimetry lying outside the conventional metrology framework from national metrology institutes but necessary to obtain traceability, repeatability, and stability of irradiations. The second consists of performing special quality assurance procedure prior to irradiation. The Oriatron eRT6 (PMB-Alcen, France) is an experimental high dose-per-pulse linear accelerator, delivering a 6 MeV pulsed electron beam with mean dose-rates, ranging from a few Gy/min up to thousands of Gy/s. Absolute dosimetry is investigated with alanine, thermo-luminescent dosimeters (TLD) and radiochromic films as well as an ionization chamber for relative stability. The beam characteristic and dosimetry are prepared for three different setups. A cross-check between alanine, films and TLD revealed a dose agreement within 3% for dose-rates between 0.078 Gy/s and 1050 Gy/s, showing that these dosimeters are suitable for absolute dosimetry for FLASH-RT. In absence of appropriate setup dependent corrections, active dosimetry can reveal dose deviations up to 15% of the prescribed dose. These differences reduce to less than 3% when our dosimetric procedure is applied. We developed procedures to accurately irradiate biological models. Our method is based on validated absolute dosimeters and extends their use to routine FLASH irradiations. We reached an agreement of 3% between the delivered and prescribed dose and developed the requirements needed for workflows of preclinical and clinical studies.

Identifiants

pubmed: 31174897
pii: S0167-8140(19)30403-7
doi: 10.1016/j.radonc.2019.05.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-39

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Patrik Gonçalves Jorge (PG)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland; Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland.

Maud Jaccard (M)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Kristoffer Petersson (K)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland; Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland.

Maude Gondré (M)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Maria Teresa Durán (MT)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Laurent Desorgher (L)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Jean-François Germond (JF)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Philippe Liger (P)

PMB-Alcen, Peynier, France.

Marie-Catherine Vozenin (MC)

Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland.

Jean Bourhis (J)

Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland.

François Bochud (F)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Raphaël Moeckli (R)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland.

Claude Bailat (C)

Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: Claude.bailat@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH